Pure Biologics S.A. (WSE:PUR)

Poland flag Poland · Delayed Price · Currency is PLN
3.584
-0.016 (-0.44%)
At close: Feb 12, 2026
Market Cap44.08M -29.3%
Revenue (ttm)n/a
Net Income-17.93M
EPS-4.52
Shares Out12.24M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume35,215
Average Volume215,122
Open3.642
Previous Close3.600
Day's Range3.580 - 3.678
52-Week Range3.100 - 17.100
Beta0.70
RSI42.02
Earnings DateApr 30, 2026

About Pure Biologics

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFβ1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the αVβ8 integrin. The company was founded in 2010 and is based in Wroclaw, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 6
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PUR
Full Company Profile

Financial Performance

Financial Statements